MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Repros Therapeutics Company Profile (NASDAQ:RPRX)

Consensus Ratings for Repros Therapeutics (NASDAQ:RPRX) (?)
Ratings Breakdown: 1 Sell Rating(s), 3 Hold Rating(s), 1 Buy Rating(s)
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $23.67 (1,369.98% upside)

Analysts' Ratings History for Repros Therapeutics (NASDAQ:RPRX)
Show:
DateFirmActionRatingPrice TargetActions
2/9/2016Piper JaffrayReiterated RatingNeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/4/2015Brean CapitalReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/30/2015Ladenburg ThalmannDowngradeBuy -> NeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/30/2015Bank of AmericaDowngradeNeutral -> UnderperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/28/2015LaidlawReiterated RatingBuy$28.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/29/2014Ascendiant Capital MarketsReiterated RatingPositiveView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/30/2014 forward)
Earnings History for Repros Therapeutics (NASDAQ:RPRX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/8/2016        
5/10/2016Q1($0.22)($0.20)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/14/2016Q4($0.27)($0.26)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/9/2015Q3($0.29)($0.27)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/10/2015Q2($0.26)($0.32)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/16/2015Q414($0.34)($0.31)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/10/2014Q314($0.39)($0.32)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/11/2014($0.37)($0.38)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/12/2014Q114($0.35)($0.37)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/13/2014Q413($0.29)($0.31)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/7/2013Q213($0.40)($0.38)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/10/2013Q1 2013($0.35)($0.41)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/18/2013Q412($0.28)($0.47)$0.00 million$0.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/13/2012Q312($0.24)($0.30)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Repros Therapeutics (NASDAQ:RPRX)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividend History for Repros Therapeutics (NASDAQ:RPRX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Repros Therapeutics (NASDAQ:RPRX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
2/18/2016Joseph PodolskiCEOBuy10,000$0.93$9,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/7/2016Joseph PodolskiCEOBuy11,677$1.18$13,778.86View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/12/2014Joseph PodolskiCEOBuy4,700$9.42$44,274.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/12/2014Katherine AndersonCFOBuy3,500$9.41$32,935.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/14/2014Joseph PodolskiCEOBuy2,100$13.91$29,211.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/14/2014Katherine AndersonCFOBuy2,000$13.85$27,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/25/2013Joseph PodolskiCEOBuy3,000$18.03$54,090.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/25/2013Katherine AndersonCFOBuy1,000$17.90$17,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/10/2013Katherine AndersonCFOBuy1,000$23.77$23,770.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/1/2013Katherine AndersonCFOBuy1,000$11.89$11,890.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Repros Therapeutics (NASDAQ:RPRX)
DateHeadline
06/30/16 06:27 PMAre Analysts Bullish Repros Therapeutics Inc (NASDAQ:RPRX) After Last Week? - Engelwood Daily
06/30/16 09:01 AMNew Broker Ratings For Repros Therapeutics Inc. (RPRX) - FTSE News
06/30/16 09:01 AMRepros Therapeutics Inc. (NASDAQ:RPRX) Company Rating and Target Watch - Telanagana Press
06/30/16 09:01 AMRepros Therapeutics Inc. (RPRX) Jumps 5.44% on June 28 - Equities.com
06/28/16 06:06 PMCheck on Share Volatility: Repros Therapeutics Inc. (NASDAQ:RPRX) - Engelwood Daily
06/28/16 06:06 PMRepros Therapeutics Incorporated (NASDAQ:RPRX) Short Interest Decreased By 16.84% - Engelwood Daily
06/27/16 10:20 AMShare Update and Earnings Review for Repros Therapeutics Inc. (NASDAQ:RPRX) - Press Telegraph
06/27/16 10:20 AMNext Weeks Broker Price Targets For Repros Therapeutics Inc. (RPRX) - Fiscal Standard
06/26/16 05:12 PMStrong Sell Calls Recommendations For Repros Therapeutics Inc. (NASDAQ:RPRX) At 0 - Investor Newswire
06/26/16 10:37 AMShare Volatility Check for: Repros Therapeutics Inc. (NASDAQ:RPRX) - Press Telegraph
06/24/16 08:46 AMWere Analysts Bullish Repros Therapeutics Inc (NASDAQ:RPRX) This Week? - Press Telegraph
06/24/16 08:46 AMCovering the Bases on Repros Therapeutics Inc. (NASDAQ:RPRX): Where is the Stock Going? - Press Telegraph
06/24/16 08:46 AMRepros Therapeutics Inc. (NASDAQ:RPRX) Earnings Glance and Target Price Review - Engelwood Daily
06/24/16 07:54 AMResearch Report Initiated on Select Biotechnology Equities -
06/20/16 07:44 AMStrong Buy Calls Count For Repros Therapeutics Inc. (NASDAQ:RPRX) At 0 - Investor Newswire
06/14/16 05:54 PMTrend Of Rating Given To Repros Therapeutics Inc. (NASDAQ:RPRX) - Investor Newswire
06/11/16 09:05 AMRepros Therapeutics Inc. (RPRX) Drops 5.32% on June 09 - Equities.com
06/10/16 06:32 PMRepros Therapeutics Inc. (RPRX) Updated Price Targets - FTSE News
06/10/16 09:12 AMRepros Therapeutics Inc. (RPRX) Drops 5.05% on June 08 - Equities.com
06/07/16 12:44 PMREPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure -
06/04/16 06:13 PMAnalyst Earnings Report: SINA Corporation (NASDAQ:SINA), Repros Therapeutics Inc. (NASDAQ:RPRX) - Beacon Chronicle
06/03/16 06:48 PMStocks Earnings Report: Repros Therapeutics Inc. (NASDAQ:RPRX), PayPal Holdings, Inc. (NASDAQ:PYPL) - Beacon Chronicle
06/03/16 06:48 PMHC Stocks Broker Alerts: Repros Therapeutics Inc (NASDAQ:RPRX), Synergy Pharmaceuticals Inc (NASDAQ:SGYP) - share market updates (press release)
06/03/16 09:07 AMShare Rating Focus on Repros Therapeutics Inc. (NASDAQ:RPRX) - HNN
06/03/16 09:07 AMAnalyst's Valuable Buzzers: Pfizer, Inc. (NYSE:PFE) , Repros Therapeutics Inc. (NASDAQ:RPRX) - Street Updates
06/02/16 06:39 PMStocks for Your Portfolio: Repros Therapeutics Inc (NASDAQ:RPRX), Medovex Corp. (NASDAQ:MDVX), Macrocure Ltd ... - The Point Review - The Point ReviewStocks for Your Portfolio: Repros Therapeutics Inc (NASDAQ:RPRX), Medovex Corp. (NASDAQ:MDVX), Macrocure Ltd ...The Point ReviewShares of Repros Therapeutics Inc (NASDAQ:RPRX) flew 22.19% to $2.07 at 12:14 PM EDT. The stock attained the volume of 3.66 Million shares recently versus average trading volume of 1.04 Million shares. If we take a look on its volatility, 7.50 percent ...and more »
06/02/16 06:39 PMThursday's Morning Insights: Repros Therapeutics Inc (RPRX), Keryx Biopharmaceuticals (KERX), and Conn's Inc ... - Smarter Analyst - Thursday's Morning Insights: Repros Therapeutics Inc (RPRX), Keryx Biopharmaceuticals (KERX), and Conn's Inc ...Smarter AnalystRepros Therapeutics Inc (NASDAQ:RPRX) is soaring nearly 19% this morning to $2.01 following yesterday's positive news that provided an update on the company's EU submission for enclomiphene. The company explained that the marketing authorization ...and more »
06/02/16 09:17 AMTarget Price and Stock Performance Rundown for Repros Therapeutics Inc. (NASDAQ:RPRX) - HNN - Target Price and Stock Performance Rundown for Repros Therapeutics Inc. (NASDAQ:RPRX)HNNDuring the latest trading session, Repros Therapeutics Inc. (NASDAQ:RPRX) shares traded -8.65%. Monitoring the stock price relative to moving averages may offer enhanced perspective on stock performance. After a recent check, shares have been seen ...and more »
06/02/16 09:17 AMTop 10 Pre-Market Gainers From Thursday - Benzinga - Top 10 Pre-Market Gainers From ThursdayBenzingaRepros Therapeutics RPRX 25.44% was trading up 19.53% after reporting success of its Enclomiphene drug to treat secondary hypogonadism. The Drug is on track for ... Joy Global Inc. JOY 9.94% traded up 9.65% after beating EPS estimates. Donaldson ...
06/01/16 06:49 PMRepros Therapeutics (RPRX) Says Enclomiphene Marketing App Submission in Europe on Track - StreetInsider.com - Repros Therapeutics (RPRX) Says Enclomiphene Marketing App Submission in Europe on TrackStreetInsider.comRepros Therapeutics Inc.® (Nasdaq: RPRX) announced that it remains on track for submission of a European centralized marketing authorization application (MAA) for enclomiphene for the treatment of secondary hypogonadism. To that end, the European ...and more »
06/01/16 06:49 PMRepros Therapeutics Inc. (RPRX) Drops 8.65% on June 01 - Equities.com - Repros Therapeutics Inc. (RPRX) Drops 8.65% on June 01Equities.comRepros Therapeutics Inc. (RPRX) was one of the Russell 2000's biggest losers for Wednesday June 01 as the stock slid 8.65% to $1.69, a loss of $-0.16 per share. Starting at an opening price of $1.81 a share, the stock traded between $1.69 and $1.87 ...and more »
06/01/16 04:31 PMRepros Therapeutics Offers Update on EU Submission of Enclomiphene for Treatment of Secondary Hypogonadism, 3-Month Interim Results for Enclomiphene Study - Repros Therapeutics Inc.® (Nasdaq: RPRX) today announced that it remains on track for submission of a European centralized marketing authorization application (MAA) for enclomiphene for the treatment of secondary hypogonadism. To that end, the European Medicines Agency (EMA) has assigned France and the UK as rapporteurs for the application review. The Company expects to submit the application in Fall 2016. As part of the review process, the Company is scheduled to meet with British and French medical reviewers in June 2016. Secondary hypogonadism is recognized in Europe. The epidemiology of the disorder, based on published evidence from the European Male Aging Study (EMAS), has been well reported and the Company believes that it is well understood amongst key European thought leaders. US Development of Enclomiphene in the Treatment of Secondary Hypogonadism The US FDA currently approves testosterone therapies for the treatment of "Classical Hypogonadism". The FDA defines this disorder as essentially a condition in which the testes are no ...Full story available on Benzinga.com
05/31/16 06:31 PMRepros Therapeutics Inc. (RPRX) Drops 6.09% on May 30 - Equities.com - Repros Therapeutics Inc. (RPRX) Drops 6.09% on May 30Equities.comRepros Therapeutics Inc. (RPRX) was one of the Russell 2000's biggest losers for Monday May 30 as the stock slid 6.09% to $1.85, a loss of $-0.12 per share. Starting at an opening price of $1.95 a share, the stock traded between $1.84 and $1.99 over ...and more »
05/29/16 04:16 PMRepros Therapeutics Inc. (NASDAQ:RPRX) Impact Score At 95 - Investor Newswire - Repros Therapeutics Inc. (NASDAQ:RPRX) Impact Score At 95Investor NewswireAlpha One explored various online articles released on Repros Therapeutics Inc. (NASDAQ:RPRX), and it set a daily sentiment score of -0.103 on the company. The entity has an algorithm in place to know stock sentiment on the share after exploring the ...and more »
05/27/16 04:43 PMStock Heading Lower Today: Repros Therapeutics Inc (NASDAQ:RPRX) - The Point Review - Stock Heading Lower Today: Repros Therapeutics Inc (NASDAQ:RPRX)The Point ReviewShare of Repros Therapeutics Inc (NASDAQ:RPRX) traded on -6.13 percent below secure line at 2:40PM EDT in order to take the company's stock at the price of $1.85. At the time of writing the stock exchanged hands 512,635.00 shares versus average ...
05/26/16 07:38 AMTarget Check and Stock Performance Recap Repros Therapeutics Inc. (NASDAQ:RPRX) - Wall Street Hints and News - Target Check and Stock Performance Recap Repros Therapeutics Inc. (NASDAQ:RPRX)Wall Street Hints and NewsTracking stock performance from various views may help with share evaluation. Some investors might be more focused on short-term share action while others may prefer to view long-term performance. In recent session activity, Repros Therapeutics Inc.and more »
05/26/16 07:38 AMInsiders Are Gradually Buying Repros Therapeutics Inc. (NASDAQ:RPRX) - Wall Street Hints and News - Insiders Are Gradually Buying Repros Therapeutics Inc. (NASDAQ:RPRX)Wall Street Hints and NewsAccording to the latest SEC filings, insiders at Repros Therapeutics Inc. (NASDAQ:RPRX) have increased their position in the stock by 53.94% over the past 6 months. Insiders now own 0.50% of total outstanding shares. There are both legal and illegal ...and more »
05/23/16 09:11 AMNoticeable Price Moves: OncoSec Medical Incorporated (PNK:ONCS) , Repros Therapeutics Inc. (NASDAQ:RPRX) - Street Updates - Noticeable Price Moves: OncoSec Medical Incorporated (PNK:ONCS) , Repros Therapeutics Inc. (NASDAQ:RPRX)Street UpdatesOn 5/20/2016, OncoSec Medical Incorporated (PNK:ONCS) ended trading session higher at $1.68 with +15.86%. The company traded a volume of 1.31 million shares as comparison to average volume of 279.68 thousand shares. During the 52 –week period, ...and more »
05/23/16 09:10 AMMovements of HC Stocks: Repros Therapeutics Inc (NASDAQ:RPRX), Lannett Company, Inc. (NYSE:LCI) - share market updates (press release) - Movements of HC Stocks: Repros Therapeutics Inc (NASDAQ:RPRX), Lannett Company, Inc. (NYSE:LCI)share market updates (press release)Shares of Repros Therapeutics Inc (NASDAQ:RPRX) ended Friday session in red amid volatile trading. The shares closed down -0.05 points or -2.36% at $2.07 with 904,592.00 shares getting traded. Post opening the session at $2.19, the shares hit an ...Repros Therapeutics Inc. (RPRX) Broker Price Targets For The Coming WeekShare Trading Newsall 3 news articles »
05/21/16 07:42 AMAnalyst Rating Fluctuations to Observe: Johnson & Johnson (NYSE:JNJ) , Repros Therapeutics Inc. (NASDAQ:RPRX) - Street Updates - Analyst Rating Fluctuations to Observe: Johnson & Johnson (NYSE:JNJ) , Repros Therapeutics Inc. (NASDAQ:RPRX)Street UpdatesOn 5/19/2016, Johnson & Johnson (NYSE:JNJ) ended trading session lower at $112.85 with -0.65%. The company traded a volume of 8.23 million shares as comparison to average volume of 7.59 million shares. During the 52 –week period, the stock's price ...and more »
05/21/16 07:42 AMRevenue Update on Repros Therapeutics Inc(NASDAQ:RPRX) - Trade Calls - CNA FinanceRevenue Update on Repros Therapeutics Inc(NASDAQ:RPRX)Trade CallsRepros Therapeutics Inc(NASDAQ:RPRX) announced the earnings results for Fiscal Year 2016 and Q1. The results came in during Pre-market on May 10, 2016. Earnings per share were $-0.20. Analysts had estimated an EPS of $-0.22. Repros Therapeutics ...15 Stocks Moving In Thursday's Pre-Market SessionBenzingaRepros Therapeutics (RPRX) Announces Positive Data for Oral Proellex in Women With Severe Menstrual BleedingStreetInsider.comHot Biotech Stocks To Watch Right Now: Gilead Sciences Inc. (GILD), Repros Therapeutics Inc. (RPRX)ZergwatchSonoran Weekly Review -The Post -Street Wise Report (press release) (blog)all 15 news articles »
05/20/16 07:48 AMAnalyst Rating Check on Repros Therapeutics Inc. (NASDAQ:RPRX) - Wall Street Hints and News - Analyst Rating Check on Repros Therapeutics Inc. (NASDAQ:RPRX)Wall Street Hints and NewsThis research may involve tracking what professional equity analysts think about the company. Currently, sell-side analysts have provided a consensus stock rating of 3 on shares of Repros Therapeutics Inc. (NASDAQ:RPRX). Analysts that cover the company ...and more »
05/20/16 07:48 AMHC Stocks Vigilant: Edwards Lifesciences Corp (NYSE:EW), Repros Therapeutics Inc (NASDAQ:RPRX), Medtronic ... - share market updates (press release) - share market updates (press release)HC Stocks Vigilant: Edwards Lifesciences Corp (NYSE:EW), Repros Therapeutics Inc (NASDAQ:RPRX), Medtronic ...share market updates (press release)Shares of Edwards Lifesciences Corp (NYSE:EW) ended Thursday session in red amid volatile trading. The shares closed down -1.97 points or -1.97% at $97.82 with 4.89 million shares getting traded. Post opening the session at $99.80, the shares hit an ...and more »
05/19/16 09:31 PMShare Performance and Target Price Review for Repros Therapeutics Inc. (NASDAQ:RPRX) - Wall Street Hints and News - Share Performance and Target Price Review for Repros Therapeutics Inc. (NASDAQ:RPRX)Wall Street Hints and NewsLooking at stock activity from multiple angles may be of benefit when examining share performance. Investors have the ability to focus in on short or long term share performance. During the most recent trading session, Repros Therapeutics Inc.and more »
05/19/16 04:24 PMInsiders Are Buying Repros Therapeutics Inc. (NASDAQ:RPRX) - Wall Street Hints and News - Insiders Are Buying Repros Therapeutics Inc. (NASDAQ:RPRX)Wall Street Hints and NewsAccording to the latest SEC filings, insiders at Repros Therapeutics Inc. (NASDAQ:RPRX) have increased their position in the stock by 56.06%. Insiders now own 0.50% of total outstanding shares. There are both legal and illegal types of insider trading.and more »
05/19/16 04:24 PM15 Stocks Moving In Thursday's Pre-Market Session - Benzinga - CNA Finance (press release)15 Stocks Moving In Thursday's Pre-Market SessionBenzingaRepros Therapeutics Inc RPRX 2.79% shares rose 34.42 percent to $2.89 in pre-market trading after the company reported positive clinical data for oral Proellex® in women with severe menstrual bleeding due to uterine fibroids. ZIOPHARM Oncology Inc.Repros Therapeutics (RPRX) Announces Positive Data for Oral Proellex in Women With Severe Menstrual BleedingStreetInsider.comRepros Therapeutics Says Proellex Study Positive (NASDAQ:RPRX)Sonoran Weekly ReviewVigorous Gainers/Losers Roundup: Repros Therapeutics (NASDAQ:RPRX), salesforce.com (NYSE:CRM), NVIDIA ...Street Wise Report (press release) (blog)Seneca Globe -CNA Finance (press release)all 9 news articles »
05/19/16 12:04 PMREPROS THERAPEUTICS INC. Financials -
05/19/16 07:34 AMRepros Therapeutics (RPRX) Announces Positive Data for Oral Proellex in Women With Severe Menstrual Bleeding - Claim your 2-week free trial to StreetInsider Premium here. Repros Therapeutics Inc.® (Nasdaq: RPRX) today reported that oral administration of Proellex® at doses of both 6 and 12 mg achieved significant reduction in excessive menstrual bleeding ...
05/18/16 04:21 PMHealthcare Volatile Stocks: Genocea Biosciences, Inc. (NASDAQ:GNCA), Repros Therapeutics Inc. (NASDAQ:RPRX ... - KC Register - Healthcare Volatile Stocks: Genocea Biosciences, Inc. (NASDAQ:GNCA), Repros Therapeutics Inc. (NASDAQ:RPRX ...KC RegisterRepros Therapeutics Inc. (NASDAQ:RPRX) announced that it has appointed Mr. Patrick Fourteau to its Board of Directors, where he will serve as Chairman of the Board. Mr. Fourteau is a seasoned pharmaceutical industry executive having over 35 years of ...and more »
05/18/16 04:21 PMRepros Therapeutics (RPRX) Announces Positive Data for Oral Proellex in Women With Severe Menstrual Bleeding - StreetInsider.com - Repros Therapeutics (RPRX) Announces Positive Data for Oral Proellex in Women With Severe Menstrual BleedingStreetInsider.comRepros Therapeutics Inc.® (Nasdaq: RPRX) today reported that oral administration of Proellex® at doses of both 6 and 12 mg achieved significant reduction in excessive menstrual bleeding, the key symptom of uterine fibroids. Normal blood loss in a ...and more »
About Repros Therapeutics

Repros Therapeutics logoRepros Therapeutics, Inc. is a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders. The Company's product candidates include Androxal and Proellex. The Company's primary product candidate Androxal is a single isomer of clomiphene citrate and an orally active proprietary small molecule compound, which is developed for the treatment of secondary hypogonadism in overweight men. The Company's Proellex product candidate for female reproductive health is a chemical entity that acts as a selective blocker of the progesterone receptor and is being developed for the treatment of symptoms associated with uterine fibroids and endometriosis.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: Pharmaceuticals
  • Exchange: NASDAQ
  • Symbol: RPRX
  • CUSIP: 76028H20
Key Metrics:
  • Previous Close: $1.61
  • 50 Day Moving Average: $1.85
  • 200 Day Moving Average: $1.44
  • P/E Ratio: N/A
  • P/E Growth: -0.08
  • Market Cap: $39.15M
  • Current Quarter EPS Consensus Estimate: $-0.75 EPS
Additional Links:
Repros Therapeutics (NASDAQ:RPRX) Chart for Thursday, June, 30, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha